By Chris Wack
Pasithea Therapeutics experienced a significant surge in share prices, more than doubling to 65 cents, as the company announced encouraging preclinical findings from two in vivo studies evaluating the anti-tumor efficacy of PAS-004 in cancer xenograft models.
Impressive Anti-Tumor Efficacy in Lung Cancer Model
The first study conducted by the biotechnology company revealed that PAS-004 exhibited dose-dependent anti-tumor efficacy in the lung cancer NCI-H1299 cell-line-derived xenograft model. Remarkably, at dose levels of 10 mg/kg and 5 mg/kg, administered once daily, PAS-004 significantly hindered tumor growth compared to the vehicle control. Furthermore, the anti-tumor efficacy of PAS-004 proved to be superior to that of binimetinib and selumetinib when taken at equivalent doses.
Promising Results in Liver Cancer Model
In the second study, PAS-004 demonstrated dose-dependent anti-tumor efficacy in the liver cancer xHepG2 cell-line-derived xenograft model. Similar to the lung cancer study, PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, showcased significant antitumor activities compared to the vehicle control. Notably, the anti-tumor efficacy of PAS-004 was found to be similar to that of binimetinib and superior to that of selumetinib when administered at equivalent doses.
Future Prospects: Phase I Study
Pasithea Therapeutics is preparing for a Phase I study, anticipated to commence as early as the first quarter of 2024. This eagerly awaited study will follow the acceptance of the company's Investigational New Drug Application with the Food and Drug Administration.
Popular
All Rights Reserved © 2024
Write Your Comment